April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Sapanisertib Not Active in Patients With TSC1/TSC2-Mutated mUC
August 2nd 2021In an interview with Targeted Oncology™, Joseph Kim, MD, an associate professor of internal medicine at the Yale School of Medicine, discuss the lack of clinical benefit of sapanisertib for the treatment of TSC1/TSC2mutated mUC.
Read More
High Urinary Cotinine Levels Correlate With Recurrence of Non-Muscle Invasive Bladder Cancer
July 14th 2021A significant increase in the risk of disease recurrence among patients with high level of the nicotine metabolite, urinary cotinine, who had non–muscle invasive bladder cancer and were smokers.
Read More
Roundtable Discussion: Defining How the JAVELIN Trial Changes Practice in Metastatic Bladder Cancer
July 9th 2021During a Targeted Oncology Case-Based Roundtable event, Daniel A. Landau, MD, moderated a discussion around the JAVELIN trial and how its results were practice changing for oncologists treating for bladder cancer.
Read More
ODAC Panel Approves 4 of 6 Anti–PD-1/PD-L1 Drugs in Accelerated Approval Program
June 16th 2021An FDA Oncologic Drugs Advisory Committee meeting resulted in continued approval for 4 of 6 indications that were discussed, although all 6 indications did not demonstrate clinical benefit in confirmatory studies. The meeting, held April 27-29, evaluated anti–PD-1/PD-L1 drugs that received accelerated approvals through the FDA’s accelerated approval program, a nearly 30-year-old initiative to expedite the approval process.
Read More
INTACT Regimen Does Not Increase Toxicity in Patients With MIBC
June 10th 2021In an interview with Targeted Oncology, Parminder Singh, MD, discussed the need for bladder-sparing therapies in an older patient population of muscle-invasive bladder cancer and the findings from the INTACT clinical trial.
Read More
Urothelial Cancer Guidelines Are Updated to Include Immune Checkpoint Inhibitors
May 17th 2021Immunotherapies are now accepted treatments in the maintenance and second-line settings for patients with metastatic urothelial cancer and in the setting of superficial UC–carcinoma in situ with prior intravesical therapy, according to updated NCCN guidelines
Read More
FDA Grants Priority Review to Adjuvant Nivolumab for High-Risk MIUC
April 30th 2021The FDA has accepted a Biologics License Application for nivolumab for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma and granted it Priority Review.
Read More
ODAC Votes to Continue Approval of Pembrolizumab For Locally Advanced or Metastatic UC
April 28th 2021The FDA’s Oncologic Drugs Advisory Committee voted 5 to 3 in favor of continued approval of pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
Read More
Avelumab Considered a Gold Standard for Advanced Urothelial Carcinoma After 1L Chemotherapy
April 23rd 2021Avelumab is considered a new standard-of-care treatment for patients with advanced urothelial carcinoma who have not progressed on frontline platinum-containing chemotherapy after the agent demonstrated overall survival improvement for this patient population in a phase 3 clinical trial setting.
Read More
Adjuvant Nivolumab Confers 30% Reduction in Disease Recurrence in MIUC
April 22nd 2021Findings from a A phase 3 trial evaluating adjuvant nivolumab following surgery versus placebo demonstrated an improvement in median disease-free survival in patients with muscle-invasive urothelial cancer, according to results from the CheckMate 274 trial presented at the 2021 Genitourinary Cancers Symposium.
Read More
FDA Grants Priority Review to Enfortumab Vedotin for Urothelial Cancer
April 19th 2021The FDA has granted priority review for 2 supplemental biologics license applications for enfortumab vedotin-ejfv for the treatment of a subset of patients with locally advanced or metastatic urothelial cancer.
Read More
FDA Accelerates Approval of Sacituzumab Govitecan in Locally Advanced or Metastatic UC
April 13th 2021An accelerated approval was granted by the FDA to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.
Read More
Avelumab Maintenance Considered for a Patient With Metastatic Urothelial Cancer
March 9th 2021During a virtual Targeted Oncology Case-Based Roundtable event, Anish B. Parikh, MD, discussed front-line treatment options for metastatic urothelial cancer as well as the data supporting avelumab maintenance.
Read More